Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

Lai, Zhicheng; He, Minjun; Bu, Xianmin; Xu, Yidan; Huang, Ye-Xing; Wen, Dongsheng; Li, Qi‐Jiong; Xu, Li; Zhang, YaoJun; Wei, Wei; Chen, Min‐shan; Kan, Anna; Shi, Ming

doi:10.1016/j.ejca.2022.07.005

Cited by 67 publications

(56 citation statements)

References 33 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, two clinical trials demonstrated that HAIC yielded signi cantly better treatment response, better survival outcomes and less AEs than TACE in the treatment for massive unresectable HCC [4,17]. The combination of HAIC with TKIs and anti-PD-1 inhibitors has been reported to be used as a therapeutic method by previous studies with favorable ORR (63.0%-67.6%), DCR (90.1%-92.6%) and PFS (10.6 months-11.63 months) [9,10,18]. Moreover, He et al [10] reported that 9 (12.7%) patients were converted to curative surgical resection owing to tumor shrinkage after the combination therapy.…”

Section: Discussionmentioning

confidence: 96%

“…Considering the different anti-tumor effect of TKIs, programmed cell death protein-1 (PD-1) inhibitors and HAIC, it may lead to promising treatment e cacy when combining these three therapeutic methods in the treatment for HCC. A combination therapy of Lenvatinib (a TKI), toripalimab (a PD-1 inhibitors) plus HAIC has been reported to have acceptable toxic effects and encouraging antitumor activity in patients with advanced HCC [9,10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma

Zhang

Feng

et al. 2023

Preprint

View full text Add to dashboard Cite

Purposes: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) immunotherapy versus combination therapy of transarterial chemotherapy (TACE), TKIs and PD-1 inhibitors in the treatment for hepatocellular carcinoma (HCC). Methods: The data of 302 patients with HCC receiving HAIC combined with TKIs and PD-1 inhibitors (HAIC-TP group) and 446 patients receiving TACE combined with TKIs and PD-1 inhibitors (TACE-TP group) were retrospectively collected. The progression-free survival (PFS), overall survival (OS), tumor response and adverse events were compared between two groups. Propensity-score matching (PSM) analysis were utilized to minimize the bias. Results: HAIC-TP group exhibited longer PFS (17.1 months versus 8.9 months, P < 0.001), longer OS (not reached versus 14.3 months, P < 0.001) and better objective response rate (RECIST: 33.1% versus 7.8%, P < 0.001; mRECIST: 51.4% versus 17.5%, P < 0.001) than TACE-TP group. Nausea, diarrhea and abdominal pain were more frequent in the HAIC-TP group, while liver dysfunction occurred more common in the TACE-TP group. PSM analysis showed the same results. Conclusions: In patients with HCC, the combination of HAIC with TKIs and anti-PD-1 immunotherapy is an effective and safe therapeutic regimen over TACE-based combination therapy. A prospective study with a large sample size is needed to validate the efficacy and safety of the combination therapy.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma

Zhang

Feng

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…With the advent of targeted and immune drugs, there is need to compare the efficacy of a combination of targeted therapy or immunotherapy with HAIC ( 53 ). This is currently a research hotspot in the field of HAIC.…”

Section: Discussionmentioning

confidence: 99%

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis

Zhang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIn recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. Although several studies have been published, no bibliometric analysis have been conducted on this topic.ObjectivesTo understand the development status and future trends in the application of HAIC, we conducted bibliometric analysis to examine the cooperation and influence among countries, institutions, authors, and journals.MethodsAll relevant articles and reviews on the use of HAIC in HCC treatment were retrieved from the Web of Science database. A bibliometric analysis of countries, institutions, journals, authors, and keywords related to this field was performed using R and VOSviewer software. The main aspects analyzed were the research status and key fields of HAIC in HCC treatment.ResultsA total of 1026 articles published in 292 journals by 4937 authors from 959 institutions between 1974 and 2021 were retrieved. A rapid increase in articles published after 1990 was observed, which reached the peak in 2021. Japan had the most publications and citations. Yonsei University, Sun Yat-sen University, and Hiroshima University were the three leading institutions in research on this topic. Kwang-Hyub Han and Masatoshi Kudo have the greatest academic influence in this field. Most publications were made in the Hepato-Gastroenterology, whereas cancer had the most citations. The main aspects of HAIC treatment of HCC include HAIC and TACE, chemotherapy drug selection, HAIC and targeted therapy and immunotherapy, HAIC and surgery, and hepatotoxicity. Keywords such as FOLFOX, lenvatinib, hepatic arterial infusion chemotherapy are hot words in this field in recent years.ConclusionThe research on the use of HAIC in the treatment of HCC has been on the rise. Currently, HAIC combined with targeted therapy or immunotherapy has attracted significant attention.

show abstract

“…A number of retrospective studies have investigated treatment with TACE plus a PD-1 inhibitor combined with lenvatinib (192)(193)(194)(195)(196)(197), and they have noted encouraging efficiency and manageable safety in patients with unresectable HCC. A phase II single center study revealed the safe and encouraging antitumor activity of HAIC plus levatinib-toripalimab in high-risk advanced HCC (198). In that trial involving 36 subjects, the primary end-point was met with a PFS rate of 80.6% (95% CI: 64.0-91.8%) at six months.…”

Section: Triple Therapy or Conversion Managementmentioning

confidence: 99%

An overview: Management of patients with advanced hepatocellular carcinoma

Wang

Sun

et al. 2022

BST

View full text Add to dashboard Cite

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

Cited by 67 publications

References 33 publications

Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma

Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis

An overview: Management of patients with advanced hepatocellular carcinoma

Contact Info

Product

Resources

About